Press Releases
Coronavirus brings dawn of digital healthcare
In light of the highly-infectious Coronavirus pandemic, healthcare systems across the world have had to adapt rapidly for the evolving situation, which has resulted in unintentionally bringing the dawn of digital healthcare.
WMG and Birmingham Hospitals launch new degree for new NHS role
WMG at the University of Warwick has launched an exciting new fusion science degree, accredited by the National School of Healthcare Science as part of Health Education England, and is designed specifically to train people for a brand new, and first of its kind health role within the NHS - Digital Healthcare Scientist.
Warwick awarded £2.3 million to help develop cutting-edge technologies for cancer diagnosis and personalised treatment
Greg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will confirm today (Tuesday 6 November) that UK Research and Innovation will invest £10 million in the PathLAKE project as part of the Industrial Strategy Challenge Fund. The University of Warwick has been awarded £2.3 million of the funding which will be used to create innovative solutions in digital pathology and Artificial Intelligence (AI) to speed up the time in which cancer is diagnosed and treated.
Using adrenaline in cardiac arrests results in less than 1% more people leaving hospital alive - but nearly doubles the survivors’ risk of severe brain damage
A clinical trial of the use of adrenaline in cardiac arrests has found that its use results in less than 1% more people leaving hospital alive - but almost doubles the risk of severe brain damage for survivors of cardiac arrest. The research raises important questions about the future use of adrenaline in such cases and will necessitate debate amongst healthcare professionals, patients and the public.
Moderate to high intensity exercise does not slow cognitive decline in people with dementia
Moderate to high intensity exercise does not slow cognitive (mental) impairment in older people with dementia, finds a trial led by a University of Warwick researcher
Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer
Study that finds women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months in preventing relapse and death, and can reduce side effects, finds new research.